Insilico Medicine says FDA grants Fast Track status to mesothelioma candidate ISM6331 after Phase I study

PUBT · 2d ago
Insilico Medicine says FDA grants Fast Track status to mesothelioma candidate ISM6331 after Phase I study
  • Insilico Medicine received FDA Fast Track designation for ISM6331 in advanced malignant pleural mesothelioma following prior immunotherapy and platinum chemotherapy.
  • Phase I first-in-human results were previously shared in early forums; additional data will be presented at ESMO 2026.
  • The designation strengthens the program’s regulatory path, supporting faster development timelines via closer FDA interaction and potential rolling submissions.
  • ISM6331 is a pan-TEAD inhibitor designed with the company’s Chemistry42 platform, positioning it as a key oncology asset in its AI-driven pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via PR Newswire (Ref. ID: CN13684) on July 29, 2026, and is solely responsible for the information contained therein.